The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 03, 2025
Filed:
Jul. 22, 2021
Applicants:
Guardant Health, Inc., Redwood City, CA (US);
Board of Regents, the University of Texas System, Austin, TX (US);
Inventors:
Scott Kopetz, Austin, TX (US);
AmirAli Talasaz, Atherton, CA (US);
Assignee:
Guardant Health, Inc., Palo Alto, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/04 (2006.01); C07K 14/71 (2006.01); C07K 14/82 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12Q 1/68 (2018.01); C12Q 1/6886 (2018.01); G16B 20/10 (2019.01); G16B 20/20 (2019.01); G16B 99/00 (2019.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); C07K 14/71 (2013.01); C07K 14/82 (2013.01); C07K 16/2863 (2013.01); C07K 16/30 (2013.01); G16B 20/10 (2019.02); G16B 20/20 (2019.02); G16B 99/00 (2019.02); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01);
Abstract
Sequence variants and copy number variations in the EGFR, KRAS and MET genes are biomarkers for resistance to anti-EGFR therapies for cancer. This disclosure provides methods of detecting these biomarkers and using them in the diagnosis and treatment of cancer.